| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tamoxifen | 55 | 2024 | 962 | 5.770 |
Why?
|
| Antineoplastic Agents, Hormonal | 57 | 2024 | 1522 | 3.990 |
Why?
|
| Breast Neoplasms | 117 | 2024 | 21019 | 3.680 |
Why?
|
| Receptors, Estrogen | 40 | 2024 | 2201 | 2.990 |
Why?
|
| Receptors, Progesterone | 27 | 2024 | 1122 | 2.670 |
Why?
|
| Aromatase Inhibitors | 24 | 2024 | 511 | 2.410 |
Why?
|
| Premenopause | 24 | 2024 | 1039 | 2.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2024 | 11656 | 2.250 |
Why?
|
| Chemotherapy, Adjuvant | 61 | 2024 | 3518 | 2.030 |
Why?
|
| Androstadienes | 14 | 2024 | 348 | 2.020 |
Why?
|
| Ovary | 11 | 2019 | 961 | 1.910 |
Why?
|
| Carcinoma, Renal Cell | 22 | 2024 | 3216 | 1.780 |
Why?
|
| Nitriles | 21 | 2024 | 954 | 1.740 |
Why?
|
| Kidney Neoplasms | 22 | 2024 | 4312 | 1.620 |
Why?
|
| Inflammatory Breast Neoplasms | 10 | 2024 | 144 | 1.560 |
Why?
|
| Receptor, erbB-2 | 28 | 2024 | 2524 | 1.530 |
Why?
|
| Prostatic Neoplasms | 67 | 2024 | 11324 | 1.470 |
Why?
|
| Triazoles | 17 | 2020 | 904 | 1.460 |
Why?
|
| Cytochrome P-450 CYP2D6 | 6 | 2016 | 105 | 1.310 |
Why?
|
| Postmenopause | 21 | 2020 | 2499 | 1.260 |
Why?
|
| Melanoma | 8 | 2024 | 5690 | 1.030 |
Why?
|
| Prostate-Specific Antigen | 36 | 2024 | 2525 | 1.020 |
Why?
|
| Ki-67 Antigen | 9 | 2019 | 631 | 0.970 |
Why?
|
| Clinical Trials as Topic | 17 | 2022 | 8050 | 0.950 |
Why?
|
| Neoplasms, Hormone-Dependent | 13 | 2018 | 411 | 0.890 |
Why?
|
| Neoplasm Recurrence, Local | 31 | 2024 | 9271 | 0.880 |
Why?
|
| Disease-Free Survival | 43 | 2024 | 6814 | 0.870 |
Why?
|
| Antineoplastic Agents | 28 | 2020 | 13625 | 0.780 |
Why?
|
| Neoplasm Staging | 34 | 2024 | 11125 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 28 | 2024 | 10329 | 0.630 |
Why?
|
| Androgen Antagonists | 13 | 2024 | 1443 | 0.630 |
Why?
|
| Aromatase | 2 | 2016 | 147 | 0.620 |
Why?
|
| Prostatectomy | 13 | 2024 | 1943 | 0.580 |
Why?
|
| Diffusion of Innovation | 1 | 2021 | 730 | 0.550 |
Why?
|
| Humans | 299 | 2024 | 759098 | 0.550 |
Why?
|
| Female | 181 | 2024 | 390174 | 0.550 |
Why?
|
| Survival Analysis | 23 | 2024 | 10181 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2024 | 6530 | 0.510 |
Why?
|
| Neoadjuvant Therapy | 13 | 2024 | 2810 | 0.500 |
Why?
|
| Prognosis | 50 | 2024 | 29559 | 0.500 |
Why?
|
| DNA, Neoplasm | 5 | 2016 | 1744 | 0.490 |
Why?
|
| Middle Aged | 154 | 2024 | 219628 | 0.480 |
Why?
|
| Taxoids | 8 | 2017 | 668 | 0.470 |
Why?
|
| Research Design | 6 | 2023 | 6165 | 0.460 |
Why?
|
| Estrogens | 2 | 2020 | 1520 | 0.430 |
Why?
|
| Aged | 129 | 2024 | 168615 | 0.430 |
Why?
|
| Clinical Trials, Phase III as Topic | 9 | 2022 | 859 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2020 | 15750 | 0.410 |
Why?
|
| Health Priorities | 1 | 2015 | 372 | 0.410 |
Why?
|
| Quality of Life | 21 | 2024 | 13285 | 0.400 |
Why?
|
| Castration | 4 | 2011 | 152 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5637 | 0.400 |
Why?
|
| Mastectomy | 10 | 2021 | 1832 | 0.390 |
Why?
|
| Leucine | 11 | 2012 | 548 | 0.380 |
Why?
|
| Treatment Outcome | 60 | 2024 | 64867 | 0.380 |
Why?
|
| Antigens, Neoplasm | 8 | 2017 | 2000 | 0.380 |
Why?
|
| Cyclophosphamide | 16 | 2023 | 2218 | 0.380 |
Why?
|
| Paclitaxel | 5 | 2024 | 1716 | 0.380 |
Why?
|
| Receptors, Steroid | 1 | 2011 | 153 | 0.370 |
Why?
|
| Risk Assessment | 16 | 2021 | 24049 | 0.360 |
Why?
|
| Receptors, Androgen | 5 | 2020 | 1074 | 0.350 |
Why?
|
| Adult | 121 | 2024 | 219353 | 0.340 |
Why?
|
| Interleukin-2 | 8 | 2014 | 1877 | 0.340 |
Why?
|
| Medical Oncology | 4 | 2021 | 2309 | 0.330 |
Why?
|
| Double-Blind Method | 19 | 2022 | 12383 | 0.330 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 580 | 0.330 |
Why?
|
| Endpoint Determination | 4 | 2020 | 597 | 0.310 |
Why?
|
| Goserelin | 9 | 2012 | 127 | 0.290 |
Why?
|
| Immunohistochemistry | 16 | 2020 | 11046 | 0.290 |
Why?
|
| Proportional Hazards Models | 15 | 2021 | 12526 | 0.290 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 5801 | 0.280 |
Why?
|
| Carboplatin | 2 | 2009 | 789 | 0.280 |
Why?
|
| Research | 1 | 2015 | 1972 | 0.280 |
Why?
|
| Nutritional Requirements | 16 | 2012 | 275 | 0.280 |
Why?
|
| Neoplasm Metastasis | 14 | 2021 | 4883 | 0.270 |
Why?
|
| Immunotherapy | 7 | 2022 | 4626 | 0.270 |
Why?
|
| Follow-Up Studies | 25 | 2022 | 39213 | 0.260 |
Why?
|
| Cryptosporidium parvum | 1 | 2005 | 37 | 0.260 |
Why?
|
| Drug Administration Schedule | 12 | 2019 | 4893 | 0.260 |
Why?
|
| Cryptosporidiosis | 1 | 2005 | 55 | 0.250 |
Why?
|
| Male | 139 | 2024 | 358602 | 0.250 |
Why?
|
| Predictive Value of Tests | 22 | 2024 | 15262 | 0.250 |
Why?
|
| Adenocarcinoma | 10 | 2011 | 6312 | 0.240 |
Why?
|
| Methotrexate | 12 | 2016 | 1715 | 0.240 |
Why?
|
| Lymphatic Metastasis | 9 | 2021 | 2943 | 0.240 |
Why?
|
| Ketoconazole | 3 | 2009 | 97 | 0.240 |
Why?
|
| Carbonic Anhydrases | 4 | 2010 | 109 | 0.240 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2024 | 81 | 0.240 |
Why?
|
| Penile Erection | 2 | 2017 | 100 | 0.240 |
Why?
|
| Erectile Dysfunction | 4 | 2018 | 452 | 0.230 |
Why?
|
| Androgens | 7 | 2011 | 1287 | 0.230 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2017 | 1588 | 0.230 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 351 | 0.230 |
Why?
|
| Prostate | 6 | 2015 | 1781 | 0.220 |
Why?
|
| Brachytherapy | 5 | 2018 | 1239 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2010 | 452 | 0.220 |
Why?
|
| Loss of Heterozygosity | 2 | 2016 | 659 | 0.220 |
Why?
|
| Biological Assay | 1 | 2006 | 630 | 0.220 |
Why?
|
| Lysine | 5 | 2012 | 1002 | 0.220 |
Why?
|
| Pyridines | 7 | 2024 | 2876 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2018 | 1785 | 0.210 |
Why?
|
| Health Policy | 1 | 2015 | 2674 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2024 | 556 | 0.210 |
Why?
|
| Time Factors | 28 | 2024 | 40083 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2022 | 10825 | 0.210 |
Why?
|
| Tumor Burden | 4 | 2018 | 1886 | 0.210 |
Why?
|
| Benzenesulfonates | 5 | 2010 | 165 | 0.210 |
Why?
|
| Survival Rate | 16 | 2020 | 12793 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 7 | 2018 | 9131 | 0.210 |
Why?
|
| Gonadotropin-Releasing Hormone | 6 | 2018 | 1155 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2024 | 1989 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2022 | 894 | 0.200 |
Why?
|
| Kallikreins | 2 | 2020 | 231 | 0.190 |
Why?
|
| Amino Acids | 7 | 2006 | 1715 | 0.190 |
Why?
|
| Aged, 80 and over | 41 | 2024 | 58864 | 0.190 |
Why?
|
| Lymph Nodes | 6 | 2019 | 3482 | 0.190 |
Why?
|
| Thymidine Kinase | 1 | 2022 | 286 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 346 | 0.190 |
Why?
|
| Teratology | 1 | 2000 | 8 | 0.180 |
Why?
|
| Methionine | 4 | 2004 | 569 | 0.180 |
Why?
|
| Models, Economic | 3 | 2020 | 717 | 0.180 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2001 | 45 | 0.180 |
Why?
|
| Prospective Studies | 26 | 2024 | 54190 | 0.180 |
Why?
|
| Mammaplasty | 2 | 2021 | 1234 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 8489 | 0.170 |
Why?
|
| Genotype | 12 | 2018 | 12940 | 0.170 |
Why?
|
| Financing, Organized | 1 | 2021 | 204 | 0.170 |
Why?
|
| Combined Modality Therapy | 8 | 2022 | 8548 | 0.170 |
Why?
|
| Estradiol | 4 | 2018 | 1931 | 0.170 |
Why?
|
| Estramustine | 3 | 2008 | 36 | 0.160 |
Why?
|
| Carcinoma | 3 | 2017 | 2335 | 0.160 |
Why?
|
| Toxicology | 1 | 1999 | 103 | 0.160 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 169 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2694 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2021 | 223 | 0.160 |
Why?
|
| Nutrition Disorders | 3 | 2004 | 205 | 0.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2011 | 131 | 0.150 |
Why?
|
| Nomograms | 2 | 2018 | 239 | 0.150 |
Why?
|
| Fluorouracil | 10 | 2012 | 1621 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 67 | 0.150 |
Why?
|
| Neoplasm Proteins | 4 | 2013 | 3614 | 0.150 |
Why?
|
| Germ Cells | 2 | 2020 | 635 | 0.150 |
Why?
|
| Retrospective Studies | 33 | 2024 | 80125 | 0.150 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2004 | 445 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2001 | 391 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2001 | 427 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15726 | 0.150 |
Why?
|
| Research Personnel | 2 | 2021 | 582 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2001 | 256 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2011 | 545 | 0.150 |
Why?
|
| Breast | 4 | 2019 | 1980 | 0.150 |
Why?
|
| Breast Implants | 1 | 2021 | 411 | 0.150 |
Why?
|
| Orgasm | 1 | 2017 | 61 | 0.140 |
Why?
|
| Disease Progression | 14 | 2024 | 13470 | 0.140 |
Why?
|
| Salvage Therapy | 3 | 2009 | 1265 | 0.140 |
Why?
|
| Oxidation-Reduction | 16 | 2006 | 2225 | 0.140 |
Why?
|
| Decision Making | 2 | 2008 | 3917 | 0.140 |
Why?
|
| Mastectomy, Segmental | 3 | 2017 | 963 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 568 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 1092 | 0.130 |
Why?
|
| Orchiectomy | 4 | 2011 | 470 | 0.130 |
Why?
|
| Regression Analysis | 6 | 2015 | 6358 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 1999 | 988 | 0.130 |
Why?
|
| Piperazines | 2 | 2024 | 2516 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7460 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2020 | 17748 | 0.130 |
Why?
|
| Mediterranean Region | 1 | 2015 | 47 | 0.130 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 1674 | 0.130 |
Why?
|
| Ovariectomy | 2 | 2019 | 611 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2020 | 6195 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2015 | 6788 | 0.130 |
Why?
|
| Telephone | 1 | 2019 | 622 | 0.130 |
Why?
|
| Risk Factors | 17 | 2020 | 74167 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 755 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2019 | 788 | 0.130 |
Why?
|
| Albumins | 1 | 2018 | 567 | 0.120 |
Why?
|
| Carbon Isotopes | 10 | 2004 | 461 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 2413 | 0.120 |
Why?
|
| Estrone | 1 | 2016 | 232 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2018 | 589 | 0.120 |
Why?
|
| Ear Neoplasms | 1 | 2015 | 118 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 168 | 0.120 |
Why?
|
| Neoplasms | 6 | 2022 | 22023 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2010 | 3476 | 0.120 |
Why?
|
| Age Factors | 10 | 2019 | 18391 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 4 | 2022 | 1031 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2023 | 8001 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2016 | 2641 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2024 | 2996 | 0.120 |
Why?
|
| Phenylalanine | 2 | 2006 | 365 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2010 | 996 | 0.120 |
Why?
|
| DNA | 2 | 2020 | 7235 | 0.120 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 321 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 908 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 2635 | 0.110 |
Why?
|
| Epirubicin | 1 | 2013 | 83 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 3618 | 0.110 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 9372 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 724 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2013 | 96 | 0.110 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 820 | 0.110 |
Why?
|
| Multivariate Analysis | 10 | 2021 | 12152 | 0.110 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1843 | 0.110 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2013 | 124 | 0.110 |
Why?
|
| Rectum | 2 | 2016 | 896 | 0.110 |
Why?
|
| Amino Acids, Sulfur | 2 | 2004 | 16 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4563 | 0.100 |
Why?
|
| Alkaline Phosphatase | 2 | 2007 | 864 | 0.100 |
Why?
|
| India | 12 | 2006 | 2344 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 937 | 0.100 |
Why?
|
| Cystine | 2 | 2004 | 94 | 0.100 |
Why?
|
| Sjogren's Syndrome | 1 | 2014 | 238 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 145 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1304 | 0.100 |
Why?
|
| Viscera | 2 | 2003 | 138 | 0.100 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2011 | 15 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2013 | 124 | 0.100 |
Why?
|
| Mutation | 10 | 2020 | 29878 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2009 | 2047 | 0.100 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 115 | 0.100 |
Why?
|
| Dietary Proteins | 3 | 2003 | 947 | 0.100 |
Why?
|
| Diet | 11 | 2012 | 8001 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 560 | 0.100 |
Why?
|
| Threonine | 2 | 2002 | 271 | 0.100 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 28 | 0.100 |
Why?
|
| Testosterone | 5 | 2011 | 2468 | 0.100 |
Why?
|
| Fertilization in Vitro | 3 | 2005 | 1296 | 0.100 |
Why?
|
| South America | 1 | 2011 | 181 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 800 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| New Zealand | 1 | 2011 | 354 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 489 | 0.090 |
Why?
|
| Urologic Diseases | 1 | 2013 | 247 | 0.090 |
Why?
|
| Pyrroles | 4 | 2010 | 1135 | 0.090 |
Why?
|
| Incidence | 6 | 2022 | 21344 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 363 | 0.090 |
Why?
|
| Cystic Fibrosis | 5 | 2004 | 1267 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2015 | 2364 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 430 | 0.090 |
Why?
|
| Organic Anion Transporters | 1 | 2011 | 100 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 61 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1087 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 317 | 0.090 |
Why?
|
| Interferon-alpha | 2 | 2005 | 918 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 151 | 0.090 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 29 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 2011 | 593 | 0.090 |
Why?
|
| Niacinamide | 5 | 2010 | 414 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2021 | 3414 | 0.090 |
Why?
|
| Branched DNA Signal Amplification Assay | 1 | 2009 | 4 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 276 | 0.090 |
Why?
|
| Hotlines | 1 | 2010 | 55 | 0.090 |
Why?
|
| Norovirus | 1 | 2010 | 36 | 0.090 |
Why?
|
| Selenium | 2 | 2011 | 416 | 0.090 |
Why?
|
| Azasteroids | 1 | 2009 | 37 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2011 | 258 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2013 | 480 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 987 | 0.080 |
Why?
|
| Cross-Over Studies | 3 | 2011 | 2058 | 0.080 |
Why?
|
| Disease Notification | 1 | 2010 | 98 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 4283 | 0.080 |
Why?
|
| Hot Flashes | 3 | 2017 | 327 | 0.080 |
Why?
|
| World Health Organization | 1 | 2015 | 1317 | 0.080 |
Why?
|
| Teratogens | 2 | 2000 | 117 | 0.080 |
Why?
|
| Oncogene Fusion | 1 | 2009 | 81 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2013 | 317 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2801 | 0.080 |
Why?
|
| Nitrogen | 2 | 2001 | 351 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2021 | 2156 | 0.080 |
Why?
|
| Ventricular Function, Right | 2 | 2004 | 610 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2021 | 3890 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3864 | 0.080 |
Why?
|
| Cohort Studies | 17 | 2019 | 41266 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 673 | 0.080 |
Why?
|
| Indoles | 4 | 2010 | 1828 | 0.080 |
Why?
|
| Biopsy | 8 | 2021 | 6770 | 0.080 |
Why?
|
| Phenylurea Compounds | 5 | 2010 | 529 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1132 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2013 | 507 | 0.080 |
Why?
|
| Internet | 2 | 2019 | 3073 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 7 | 2020 | 5499 | 0.080 |
Why?
|
| Menopause | 3 | 2011 | 1640 | 0.080 |
Why?
|
| Biopsy, Needle | 4 | 2010 | 1631 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 5214 | 0.080 |
Why?
|
| Alleles | 3 | 2015 | 6896 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 6070 | 0.080 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2007 | 307 | 0.080 |
Why?
|
| Hepatitis A Vaccines | 1 | 2007 | 26 | 0.080 |
Why?
|
| Consensus | 1 | 2018 | 3091 | 0.080 |
Why?
|
| Genes, myc | 1 | 2009 | 395 | 0.080 |
Why?
|
| Gastroenteritis | 1 | 2010 | 238 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 1146 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 1052 | 0.080 |
Why?
|
| North America | 1 | 2011 | 1282 | 0.070 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2008 | 90 | 0.070 |
Why?
|
| Australia | 1 | 2011 | 1287 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2012 | 618 | 0.070 |
Why?
|
| Spin Labels | 1 | 2009 | 335 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2016 | 10427 | 0.070 |
Why?
|
| Cholesterol | 1 | 2017 | 2922 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2012 | 1218 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 700 | 0.070 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 2519 | 0.070 |
Why?
|
| Uncertainty | 1 | 2012 | 754 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1715 | 0.070 |
Why?
|
| RNA | 1 | 2017 | 2719 | 0.070 |
Why?
|
| Hepatitis A | 1 | 2007 | 133 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1187 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2020 | 3728 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2008 | 283 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 449 | 0.070 |
Why?
|
| Self Report | 2 | 2016 | 3699 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 625 | 0.070 |
Why?
|
| Valine | 2 | 2006 | 408 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2000 | 338 | 0.070 |
Why?
|
| Anthropometry | 6 | 2012 | 1344 | 0.070 |
Why?
|
| Vomiting | 1 | 2010 | 646 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2010 | 509 | 0.070 |
Why?
|
| Quadriplegia | 1 | 2008 | 226 | 0.070 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2017 | 62 | 0.070 |
Why?
|
| Pregnancy Rate | 2 | 2009 | 650 | 0.070 |
Why?
|
| Models, Biological | 4 | 2013 | 9460 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2013 | 2202 | 0.070 |
Why?
|
| South Africa | 1 | 2011 | 1810 | 0.070 |
Why?
|
| Linear Models | 8 | 2009 | 5876 | 0.070 |
Why?
|
| Arsenicals | 1 | 2006 | 116 | 0.070 |
Why?
|
| Imidazolidines | 1 | 2005 | 38 | 0.070 |
Why?
|
| Wales | 1 | 2005 | 86 | 0.070 |
Why?
|
| Colorectal Neoplasms | 3 | 2013 | 6853 | 0.070 |
Why?
|
| Influenza, Human | 2 | 2011 | 1534 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2009 | 1796 | 0.060 |
Why?
|
| Antineoplastic Protocols | 2 | 2020 | 50 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 1048 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2005 | 42 | 0.060 |
Why?
|
| Vinblastine | 1 | 2007 | 487 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1708 | 0.060 |
Why?
|
| Chloride Channels | 2 | 2004 | 218 | 0.060 |
Why?
|
| Infusions, Intravenous | 6 | 2013 | 2234 | 0.060 |
Why?
|
| Models, Theoretical | 3 | 2019 | 3556 | 0.060 |
Why?
|
| International Cooperation | 1 | 2012 | 1435 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 2 | 2003 | 935 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 377 | 0.060 |
Why?
|
| Proline | 1 | 2006 | 456 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 496 | 0.060 |
Why?
|
| Europe | 1 | 2011 | 3427 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 302 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2016 | 241 | 0.060 |
Why?
|
| Zoonoses | 1 | 2005 | 179 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 401 | 0.060 |
Why?
|
| United States | 10 | 2021 | 72238 | 0.060 |
Why?
|
| Young Adult | 9 | 2020 | 58477 | 0.060 |
Why?
|
| Early Detection of Cancer | 3 | 2015 | 3203 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 1631 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2010 | 2617 | 0.060 |
Why?
|
| Water Supply | 1 | 2005 | 208 | 0.060 |
Why?
|
| England | 1 | 2005 | 525 | 0.060 |
Why?
|
| Lidocaine | 2 | 2000 | 538 | 0.060 |
Why?
|
| School Health Services | 1 | 2007 | 382 | 0.060 |
Why?
|
| Coronary Artery Bypass | 3 | 2004 | 2274 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2009 | 1019 | 0.060 |
Why?
|
| Formaldehyde | 2 | 2016 | 358 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 716 | 0.060 |
Why?
|
| Acid Phosphatase | 1 | 2003 | 139 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 979 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2008 | 797 | 0.060 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2003 | 64 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1059 | 0.060 |
Why?
|
| Community Health Services | 1 | 2008 | 653 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2012 | 2028 | 0.060 |
Why?
|
| Soybean Proteins | 1 | 2003 | 55 | 0.060 |
Why?
|
| Catheter Ablation | 2 | 2007 | 2749 | 0.050 |
Why?
|
| Finasteride | 1 | 2004 | 90 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 20027 | 0.050 |
Why?
|
| Sirolimus | 2 | 2007 | 1537 | 0.050 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2006 | 263 | 0.050 |
Why?
|
| Remission Induction | 2 | 2006 | 2388 | 0.050 |
Why?
|
| Disease Outbreaks | 2 | 2010 | 1757 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2013 | 58 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2007 | 1612 | 0.050 |
Why?
|
| Health Care Costs | 3 | 2018 | 3253 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2005 | 2294 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 68 | 0.050 |
Why?
|
| Antioxidants | 1 | 2011 | 1666 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2016 | 6531 | 0.050 |
Why?
|
| Vaccination | 2 | 2007 | 3354 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2009 | 2857 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 620 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1116 | 0.050 |
Why?
|
| Ovarian Follicle | 1 | 2004 | 242 | 0.050 |
Why?
|
| Infertility | 1 | 2009 | 654 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 434 | 0.050 |
Why?
|
| Maternal Age | 1 | 2005 | 806 | 0.050 |
Why?
|
| Body Weight | 4 | 2017 | 4606 | 0.050 |
Why?
|
| Calorimetry, Indirect | 4 | 2003 | 174 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2002 | 125 | 0.050 |
Why?
|
| Stem Cells | 1 | 2015 | 3523 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2925 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 3448 | 0.050 |
Why?
|
| Live Birth | 1 | 2005 | 513 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 14439 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 726 | 0.050 |
Why?
|
| Fatigue | 3 | 2017 | 1543 | 0.050 |
Why?
|
| Odds Ratio | 4 | 2018 | 9712 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2004 | 698 | 0.050 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2003 | 177 | 0.050 |
Why?
|
| Anilides | 1 | 2004 | 409 | 0.050 |
Why?
|
| Dietary Carbohydrates | 2 | 2003 | 893 | 0.050 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 680 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3317 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 1230 | 0.050 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2932 | 0.050 |
Why?
|
| Adolescent | 13 | 2020 | 87551 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4492 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 546 | 0.050 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2000 | 29 | 0.050 |
Why?
|
| Tryptophan | 1 | 2003 | 480 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 415 | 0.050 |
Why?
|
| Bronchial Spasm | 1 | 2000 | 72 | 0.050 |
Why?
|
| Chlorides | 1 | 2003 | 664 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2011 | 2610 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1132 | 0.040 |
Why?
|
| Systole | 1 | 2002 | 947 | 0.040 |
Why?
|
| Gene Expression | 1 | 2013 | 7583 | 0.040 |
Why?
|
| Uridine | 1 | 2000 | 142 | 0.040 |
Why?
|
| Breath Tests | 4 | 2003 | 297 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2000 | 65 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2024 | 495 | 0.040 |
Why?
|
| Ammonium Chloride | 1 | 1999 | 72 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1152 | 0.040 |
Why?
|
| Caseins | 1 | 2000 | 103 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2179 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2002 | 1097 | 0.040 |
Why?
|
| American Medical Association | 1 | 2020 | 60 | 0.040 |
Why?
|
| Mitoxantrone | 3 | 2007 | 149 | 0.040 |
Why?
|
| Nipples | 1 | 2021 | 221 | 0.040 |
Why?
|
| Albuterol | 1 | 2000 | 212 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 2627 | 0.040 |
Why?
|
| Age Distribution | 1 | 2005 | 2891 | 0.040 |
Why?
|
| Nootropic Agents | 1 | 2000 | 157 | 0.040 |
Why?
|
| Seasons | 1 | 2005 | 1523 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 244 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2018 | 12871 | 0.040 |
Why?
|
| Cell Line, Tumor | 6 | 2013 | 16878 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2010 | 6239 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2012 | 3388 | 0.040 |
Why?
|
| Anticipation, Genetic | 1 | 1998 | 5 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1429 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 202 | 0.040 |
Why?
|
| Animals | 13 | 2022 | 167531 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 6490 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 801 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 2052 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2003 | 1992 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 152 | 0.040 |
Why?
|
| Choline | 1 | 2000 | 512 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 628 | 0.040 |
Why?
|
| Pregnancy | 6 | 2020 | 29650 | 0.040 |
Why?
|
| Tyrosine | 1 | 2003 | 1440 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1999 | 354 | 0.040 |
Why?
|
| Cysteine | 2 | 2000 | 892 | 0.040 |
Why?
|
| Reference Values | 5 | 2004 | 4914 | 0.040 |
Why?
|
| Comorbidity | 2 | 2013 | 10550 | 0.040 |
Why?
|
| Tachycardia | 1 | 2000 | 603 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2012 | 3959 | 0.040 |
Why?
|
| Fasting | 5 | 2003 | 1603 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 1362 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2004 | 762 | 0.040 |
Why?
|
| Registries | 1 | 2014 | 8435 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2008 | 3531 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2003 | 1604 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 298 | 0.040 |
Why?
|
| Risk | 4 | 2018 | 9622 | 0.040 |
Why?
|
| Pancreas | 1 | 2004 | 1674 | 0.040 |
Why?
|
| Urea | 1 | 1999 | 441 | 0.040 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 265 | 0.040 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2001 | 538 | 0.040 |
Why?
|
| General Surgery | 1 | 2008 | 1680 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2002 | 1108 | 0.040 |
Why?
|
| Ileum | 1 | 1999 | 556 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2004 | 1100 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2000 | 506 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Malnutrition | 1 | 2003 | 637 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2004 | 910 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2004 | 840 | 0.040 |
Why?
|
| Magnesium | 1 | 2000 | 810 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2009 | 3602 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 4922 | 0.040 |
Why?
|
| Logistic Models | 5 | 2011 | 13309 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2019 | 362 | 0.030 |
Why?
|
| Survivors | 1 | 2007 | 2355 | 0.030 |
Why?
|
| Glycine | 1 | 2000 | 662 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3754 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2004 | 3617 | 0.030 |
Why?
|
| Polymethacrylic Acids | 1 | 1996 | 32 | 0.030 |
Why?
|
| Chewing Gum | 1 | 1996 | 40 | 0.030 |
Why?
|
| Nasal Mucosa | 3 | 2004 | 413 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2001 | 724 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4111 | 0.030 |
Why?
|
| Carbon Dioxide | 4 | 2001 | 1144 | 0.030 |
Why?
|
| Observer Variation | 2 | 2019 | 2596 | 0.030 |
Why?
|
| Biometry | 1 | 1999 | 558 | 0.030 |
Why?
|
| Fixatives | 1 | 2016 | 91 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9587 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 748 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2020 | 375 | 0.030 |
Why?
|
| Melatonin | 1 | 2001 | 668 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15662 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 6538 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2013 | 12106 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2020 | 612 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2001 | 1665 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2001 | 982 | 0.030 |
Why?
|
| Sweating | 1 | 2016 | 154 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2009 | 2799 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1702 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2004 | 1357 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2011 | 41932 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3272 | 0.030 |
Why?
|
| Polyvinyls | 1 | 1996 | 153 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2532 | 0.030 |
Why?
|
| Checklist | 1 | 2022 | 826 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2022 | 1330 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2001 | 1265 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 2001 | 895 | 0.030 |
Why?
|
| Urinalysis | 1 | 2017 | 368 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2017 | 283 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 1996 | 118 | 0.030 |
Why?
|
| Monocytes | 1 | 2004 | 2568 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 1996 | 145 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2022 | 881 | 0.030 |
Why?
|
| Case-Control Studies | 5 | 2018 | 21992 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2008 | 3460 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 776 | 0.030 |
Why?
|
| Benzamides | 1 | 2020 | 1369 | 0.030 |
Why?
|
| Thiazoles | 1 | 2022 | 1501 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 1995 | 223 | 0.030 |
Why?
|
| Mice | 8 | 2015 | 80993 | 0.030 |
Why?
|
| Medical History Taking | 2 | 2004 | 773 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 296 | 0.030 |
Why?
|
| Infant | 5 | 2011 | 35940 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 796 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1603 | 0.030 |
Why?
|
| Clonidine | 1 | 1995 | 170 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2018 | 5067 | 0.030 |
Why?
|
| Pericarditis, Constrictive | 1 | 1994 | 46 | 0.030 |
Why?
|
| Patient Selection | 1 | 2006 | 4268 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2001 | 771 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1772 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 3960 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2004 | 1994 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2024 | 3201 | 0.030 |
Why?
|
| Refugees | 1 | 2002 | 594 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 8950 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2013 | 165 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 2000 | 1001 | 0.030 |
Why?
|
| Oxazoles | 1 | 1995 | 197 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 750 | 0.030 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 1384 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2004 | 1581 | 0.030 |
Why?
|
| Saccades | 1 | 1995 | 233 | 0.030 |
Why?
|
| Heterozygote | 3 | 2004 | 2796 | 0.030 |
Why?
|
| Hormones | 1 | 2017 | 867 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2018 | 1186 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1583 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2001 | 2837 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1719 | 0.030 |
Why?
|
| Health Surveys | 1 | 2003 | 4059 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2001 | 2198 | 0.030 |
Why?
|
| Respiratory Tract Infections | 2 | 2004 | 1001 | 0.030 |
Why?
|
| Obesity | 2 | 2012 | 12896 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2000 | 1328 | 0.030 |
Why?
|
| Enoxaparin | 1 | 1995 | 397 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2009 | 2499 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1999 | 2698 | 0.030 |
Why?
|
| Viral Load | 1 | 2001 | 3317 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1180 | 0.030 |
Why?
|
| Communication | 1 | 2006 | 3846 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1007 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2001 | 1076 | 0.020 |
Why?
|
| Food | 3 | 2003 | 773 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3822 | 0.020 |
Why?
|
| Fetus | 1 | 1999 | 1862 | 0.020 |
Why?
|
| Deuterium | 2 | 2003 | 101 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2011 | 40 | 0.020 |
Why?
|
| Ifosfamide | 2 | 2003 | 232 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2002 | 2128 | 0.020 |
Why?
|
| Retreatment | 1 | 2013 | 599 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2015 | 4037 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 451 | 0.020 |
Why?
|
| Blood Cells | 1 | 2013 | 304 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2013 | 280 | 0.020 |
Why?
|
| Forecasting | 2 | 2011 | 2928 | 0.020 |
Why?
|
| Child | 7 | 2011 | 79604 | 0.020 |
Why?
|
| Synovitis | 1 | 1993 | 216 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2010 | 26099 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 204 | 0.020 |
Why?
|
| Dairying | 1 | 1991 | 12 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2004 | 2066 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 265 | 0.020 |
Why?
|
| Nicotine | 1 | 1996 | 677 | 0.020 |
Why?
|
| Mitral Valve | 1 | 1999 | 1485 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 550 | 0.020 |
Why?
|
| Pandemics | 1 | 2011 | 8604 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2018 | 2914 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 366 | 0.020 |
Why?
|
| Etoposide | 2 | 2003 | 628 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2014 | 316 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 1998 | 1057 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3469 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 1991 | 126 | 0.020 |
Why?
|
| Epithelium | 1 | 2015 | 1604 | 0.020 |
Why?
|
| Probability | 2 | 2009 | 2474 | 0.020 |
Why?
|
| Paper | 1 | 2010 | 85 | 0.020 |
Why?
|
| Recurrence | 2 | 2018 | 8465 | 0.020 |
Why?
|
| Physicians | 1 | 2008 | 4583 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 15815 | 0.020 |
Why?
|
| Axilla | 1 | 2013 | 617 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2008 | 18094 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2011 | 240 | 0.020 |
Why?
|
| Chronic Disease | 5 | 2004 | 9245 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.020 |
Why?
|
| General Practice | 1 | 2011 | 98 | 0.020 |
Why?
|
| Health Services | 1 | 1995 | 754 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1999 | 1420 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1155 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 401 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 8633 | 0.020 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2009 | 99 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2011 | 256 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7290 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2895 | 0.020 |
Why?
|
| Clomiphene | 1 | 2009 | 71 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 756 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3793 | 0.020 |
Why?
|
| Liposomes | 1 | 2013 | 777 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 2852 | 0.020 |
Why?
|
| Kinetics | 3 | 2002 | 6373 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 138 | 0.020 |
Why?
|
| Fertility Agents, Female | 1 | 2009 | 101 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2003 | 691 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 165 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2009 | 152 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 917 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2009 | 101 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 1521 | 0.020 |
Why?
|
| Body Composition | 2 | 2012 | 2414 | 0.020 |
Why?
|
| SOXC Transcription Factors | 1 | 2008 | 41 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2013 | 719 | 0.020 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2009 | 198 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 718 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 9501 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2009 | 242 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 36164 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3616 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2008 | 176 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 1111 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2007 | 2062 | 0.020 |
Why?
|
| Longevity | 1 | 2015 | 1046 | 0.020 |
Why?
|
| Endocrine System | 1 | 2008 | 112 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 293 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 1967 | 0.020 |
Why?
|
| Hand | 1 | 1993 | 903 | 0.020 |
Why?
|
| beta Catenin | 1 | 2013 | 1045 | 0.020 |
Why?
|
| Hypotension | 1 | 2013 | 882 | 0.020 |
Why?
|
| Phenotype | 3 | 2016 | 16524 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2009 | 275 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2006 | 8530 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 2119 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 788 | 0.020 |
Why?
|
| Genetic Services | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2006 | 137 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2016 | 1341 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 816 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 2086 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2016 | 1937 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 1876 | 0.020 |
Why?
|
| Warfarin | 1 | 1995 | 1516 | 0.020 |
Why?
|
| Rehabilitation Centers | 1 | 2008 | 248 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1999 | 3824 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15639 | 0.020 |
Why?
|
| Isoleucine | 1 | 2006 | 110 | 0.020 |
Why?
|
| Massachusetts | 1 | 2019 | 8788 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 239 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1914 | 0.020 |
Why?
|
| Asthma | 2 | 2004 | 6159 | 0.020 |
Why?
|
| Feces | 2 | 2003 | 1462 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 1948 | 0.020 |
Why?
|
| Population Groups | 1 | 2006 | 211 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 806 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1341 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 2761 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 1243 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 2062 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 2814 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 629 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 436 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2008 | 625 | 0.010 |
Why?
|
| Genomics | 1 | 2020 | 5778 | 0.010 |
Why?
|
| Necrosis | 1 | 2009 | 1613 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2912 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2014 | 1600 | 0.010 |
Why?
|
| Faculty | 1 | 2007 | 382 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2004 | 394 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 616 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 1991 | 640 | 0.010 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 112 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 10746 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1183 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3091 | 0.010 |
Why?
|
| Social Adjustment | 1 | 2006 | 632 | 0.010 |
Why?
|
| Milrinone | 1 | 2004 | 86 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 5310 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 2003 | 59 | 0.010 |
Why?
|
| Lens Plant | 1 | 2003 | 5 | 0.010 |
Why?
|
| Epidermis | 1 | 2006 | 529 | 0.010 |
Why?
|
| Placebos | 2 | 2000 | 1672 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 2013 | 0.010 |
Why?
|
| Exercise | 1 | 2000 | 5774 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1438 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 178 | 0.010 |
Why?
|
| Ion Transport | 1 | 2004 | 318 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 1125 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 679 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 1757 | 0.010 |
Why?
|
| Sweat | 1 | 2003 | 54 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 1756 | 0.010 |
Why?
|
| Interferons | 1 | 2007 | 705 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 5628 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 2003 | 111 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1489 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 2002 | 158 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2003 | 104 | 0.010 |
Why?
|
| Yugoslavia | 1 | 2002 | 23 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2007 | 1422 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2009 | 1358 | 0.010 |
Why?
|
| Infant Formula | 1 | 2004 | 193 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1991 | 1484 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2004 | 357 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2004 | 326 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 2003 | 262 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2009 | 3603 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 1999 | 0.010 |
Why?
|
| Radioactive Tracers | 1 | 2002 | 66 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2038 | 0.010 |
Why?
|
| Cell Division | 1 | 2009 | 4445 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 457 | 0.010 |
Why?
|
| Divorce | 1 | 2001 | 77 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 1527 | 0.010 |
Why?
|
| Neutropenia | 1 | 2007 | 885 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 1114 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.010 |
Why?
|
| Filgrastim | 1 | 2001 | 132 | 0.010 |
Why?
|
| Organ Size | 1 | 2006 | 2247 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2001 | 134 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 662 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2434 | 0.010 |
Why?
|
| Cytidine Triphosphate | 1 | 2000 | 17 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2004 | 1095 | 0.010 |
Why?
|
| Uridine Triphosphate | 1 | 2000 | 28 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 589 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 4625 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 580 | 0.010 |
Why?
|
| Thrombosis | 1 | 1995 | 3042 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2006 | 1112 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1826 | 0.010 |
Why?
|
| Keto Acids | 1 | 2000 | 34 | 0.010 |
Why?
|
| Cytidine | 1 | 2000 | 64 | 0.010 |
Why?
|
| Epinephrine | 1 | 2004 | 791 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2000 | 318 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2001 | 225 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6763 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 3107 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3772 | 0.010 |
Why?
|
| Anesthesia, Inhalation | 1 | 2000 | 220 | 0.010 |
Why?
|
| Rabbits | 1 | 2006 | 4772 | 0.010 |
Why?
|
| Diet, Protein-Restricted | 1 | 2000 | 73 | 0.010 |
Why?
|
| Tritium | 1 | 2000 | 707 | 0.010 |
Why?
|
| Mesentery | 1 | 2000 | 203 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2006 | 1228 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4123 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1995 | 6174 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2001 | 653 | 0.010 |
Why?
|
| Vaccines | 1 | 2007 | 833 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 1546 | 0.010 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 395 | 0.010 |
Why?
|
| Ileostomy | 1 | 1999 | 119 | 0.010 |
Why?
|
| Sodium | 1 | 2004 | 1602 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2004 | 1807 | 0.010 |
Why?
|
| Minority Groups | 1 | 2006 | 1198 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2582 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 25853 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2004 | 2420 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2448 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2000 | 557 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 526 | 0.010 |
Why?
|
| Affect | 1 | 2006 | 1479 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2010 | 3664 | 0.010 |
Why?
|
| Cognition | 1 | 2016 | 6939 | 0.010 |
Why?
|
| Nutrition Policy | 1 | 2002 | 470 | 0.010 |
Why?
|
| Heart Rate | 2 | 2004 | 4165 | 0.010 |
Why?
|
| Body Temperature | 1 | 2001 | 777 | 0.010 |
Why?
|
| Sample Size | 1 | 2001 | 839 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2283 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 6964 | 0.010 |
Why?
|
| Glucagon | 1 | 2000 | 531 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2004 | 1195 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2001 | 1574 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2218 | 0.010 |
Why?
|
| Sex Factors | 2 | 2001 | 10515 | 0.010 |
Why?
|
| Students | 1 | 2007 | 1718 | 0.010 |
Why?
|
| Fertilization | 1 | 1998 | 198 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6143 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 1154 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1993 | 3772 | 0.010 |
Why?
|
| Isoflurane | 1 | 2000 | 383 | 0.010 |
Why?
|
| Rats | 2 | 2006 | 23577 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 1483 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2008 | 2509 | 0.010 |
Why?
|
| Depression | 1 | 2017 | 8026 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2009 | 2035 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2003 | 1476 | 0.010 |
Why?
|
| Death | 1 | 2001 | 677 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 4412 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 9334 | 0.010 |
Why?
|
| Counseling | 1 | 2004 | 1550 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 2141 | 0.010 |
Why?
|
| Hospitals | 1 | 2010 | 3929 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 8312 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1783 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2004 | 1804 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2002 | 1137 | 0.010 |
Why?
|
| Action Potentials | 1 | 2003 | 1810 | 0.010 |
Why?
|
| Expectorants | 1 | 1995 | 21 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 1919 | 0.010 |
Why?
|
| Insulin | 2 | 2000 | 6589 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 572 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 7593 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2001 | 2315 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2821 | 0.010 |
Why?
|
| Sarcoma | 1 | 2006 | 1786 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 2256 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 2126 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2000 | 1253 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 2309 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 1904 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 1516 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2004 | 8520 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2002 | 1394 | 0.010 |
Why?
|
| Pericardiectomy | 1 | 1994 | 46 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8582 | 0.010 |
Why?
|
| Brain | 1 | 2001 | 26860 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7247 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2004 | 4164 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3684 | 0.010 |
Why?
|
| Decision Trees | 1 | 1995 | 506 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 3797 | 0.010 |
Why?
|
| Markov Chains | 1 | 1996 | 972 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8936 | 0.010 |
Why?
|
| Tourniquets | 1 | 1993 | 110 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 7379 | 0.010 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1995 | 530 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 4970 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3235 | 0.010 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 1991 | 11 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2004 | 3854 | 0.010 |
Why?
|
| Poverty | 1 | 2003 | 2679 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 5954 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 7514 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 14648 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 21892 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 4527 | 0.010 |
Why?
|
| Rural Health | 1 | 1991 | 300 | 0.010 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 1991 | 144 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2869 | 0.010 |
Why?
|
| Health Status | 1 | 2002 | 4079 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 2567 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 11903 | 0.000 |
Why?
|
| New York | 1 | 1991 | 874 | 0.000 |
Why?
|
| Drug Prescriptions | 1 | 1996 | 1673 | 0.000 |
Why?
|
| Kidney | 1 | 2000 | 7028 | 0.000 |
Why?
|
| Parents | 1 | 1998 | 3546 | 0.000 |
Why?
|
| Smoking Cessation | 1 | 1996 | 2059 | 0.000 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 6643 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1995 | 2537 | 0.000 |
Why?
|
| Smoking | 1 | 1996 | 9066 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1991 | 4389 | 0.000 |
Why?
|
| Hospitalization | 1 | 1995 | 10732 | 0.000 |
Why?
|